Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4928 |
Name | intrahepatic cholangiocarcinoma |
Definition | A cholangiocarcinoma that arises from the intrahepatic bile duct epithelium in any site of the intrahepatic biliary tree. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer biliary tract cancer bile duct cancer bile duct carcinoma bile duct adenocarcinoma cholangiocarcinoma intrahepatic cholangiocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR2 fusion | Derazantinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
IDH1 R132S | Dasatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
IDH1 R132S | Saracatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
IDH1 R132C | Saracatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
IDH1 R132C | Dasatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 F276C | Infigratinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 fusion FGFR2 M538I | Infigratinib | intrahepatic cholangiocarcinoma | decreased response | detail... |
FGFR2 fusion FGFR2 N550H | Infigratinib | intrahepatic cholangiocarcinoma | decreased response | detail... |
FGFR2 fusion FGFR2 E566A | Infigratinib | intrahepatic cholangiocarcinoma | decreased response | detail... |
FGFR2 fusion FGFR2 H683L | Infigratinib | intrahepatic cholangiocarcinoma | decreased response | detail... |
FGFR2 fusion FGFR2 N550K | Infigratinib | intrahepatic cholangiocarcinoma | resistant | detail... |
FGFR2 fusion FGFR2 V565F | Infigratinib | intrahepatic cholangiocarcinoma | resistant | detail... |
FGFR2 fusion FGFR2 L618V | Infigratinib | intrahepatic cholangiocarcinoma | resistant | detail... |
FGFR2 fusion FGFR2 K660M | Infigratinib | intrahepatic cholangiocarcinoma | resistant | detail... |
FGFR2 fusion FGFR2 K715R | Infigratinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 fusion FGFR2 K715R | Zoligratinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 fusion FGFR2 M538I | Zoligratinib | intrahepatic cholangiocarcinoma | decreased response | detail... |
FGFR2 fusion FGFR2 N550H | Zoligratinib | intrahepatic cholangiocarcinoma | decreased response | detail... |
FGFR2 fusion FGFR2 V565F | Zoligratinib | intrahepatic cholangiocarcinoma | decreased response | detail... |
FGFR2 fusion FGFR2 E566A | Zoligratinib | intrahepatic cholangiocarcinoma | decreased response | detail... |
FGFR2 fusion FGFR2 H683L | Zoligratinib | intrahepatic cholangiocarcinoma | decreased response | detail... |
FGFR2 fusion FGFR2 N550K | Zoligratinib | intrahepatic cholangiocarcinoma | resistant | detail... |
FGFR2 fusion FGFR2 L618V | Zoligratinib | intrahepatic cholangiocarcinoma | resistant | detail... |
FGFR2 fusion FGFR2 K660M | Zoligratinib | intrahepatic cholangiocarcinoma | resistant | detail... |
FGFR2 fusion FGFR2 V565F | Futibatinib | intrahepatic cholangiocarcinoma | resistant | detail... |
FGFR2 fusion FGFR2 K715R | Futibatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 fusion FGFR2 M538I | Futibatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 fusion FGFR2 N550H | Futibatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 fusion FGFR2 N550K | Futibatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 fusion FGFR2 E566A | Futibatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 fusion FGFR2 L618V | Futibatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 fusion FGFR2 K660M | Futibatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 fusion FGFR2 H683L | Futibatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 H167_N173del | Zoligratinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 H167_N173del FGFR2 L617F | Zoligratinib | intrahepatic cholangiocarcinoma | predicted - resistant | detail... |
RET fusion | Pralsetinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 Y376C | Fexagratinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 fusion | Futibatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 rearrange | Futibatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
BRAF V600E | Trametinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR1 N546D | Futibatinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 H167_N173del | Futibatinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 I288_E295delinsT | Zoligratinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 H167_N173del FGFR2 L618F | Zoligratinib | intrahepatic cholangiocarcinoma | predicted - resistant | detail... |
FGFR2 H167_N173del FGFR2 L618F | Futibatinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
BRAF L597Q FGFR2 H167_N173del FGFR2 L618F | Futibatinib | intrahepatic cholangiocarcinoma | predicted - resistant | detail... |
BRAF L597Q FGFR2 H167_N173del FGFR2 L618F | LY3214996 | intrahepatic cholangiocarcinoma | no benefit | detail... |
BRAF L597Q FGFR2 H167_N173del FGFR2 N550K FGFR2 L618F NRAS Q61K | LY3214996 | intrahepatic cholangiocarcinoma | predicted - resistant | detail... |
MLH1 negative | Dostarlimab-gxly | intrahepatic cholangiocarcinoma | sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | intrahepatic cholangiocarcinoma | sensitive | detail... |
MLH1 negative | Pembrolizumab | intrahepatic cholangiocarcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 F276C | Pazopanib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
IDH1 act mut | Olutasidenib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 W290C | Futibatinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 C383R | Futibatinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR1 M563T | Futibatinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 mutant | Derazantinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 amp | Derazantinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 C382R | Pemigatinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
IDH1 R132C IDH2 R172K | Ivosidenib | intrahepatic cholangiocarcinoma | predicted - resistant | detail... |
IDH1 R132C IDH1 D279N | Ivosidenib | intrahepatic cholangiocarcinoma | predicted - resistant | detail... |
IDH1 R132C | Olaparib + Radiotherapy | intrahepatic cholangiocarcinoma | sensitive | detail... |
IDH1 R132H | Olaparib + Radiotherapy | intrahepatic cholangiocarcinoma | sensitive | detail... |
EML4 - ALK | Ensartinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 fusion | HMPL-453 | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR1 over exp | Infigratinib | intrahepatic cholangiocarcinoma | no benefit | detail... |
FGFR1 over exp | Futibatinib | intrahepatic cholangiocarcinoma | no benefit | detail... |
FGFR1 over exp | Pemigatinib | intrahepatic cholangiocarcinoma | no benefit | detail... |
FGFR2 T370_A371delinsC | Lenvatinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 fusion | 3HP-2827 | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
RET fusion | Selpercatinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR3 S249C FGFR3 N540K | Futibatinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 C382R | Erdafitinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 C382R FGFR2 N550D | Erdafitinib | intrahepatic cholangiocarcinoma | predicted - resistant | detail... |
FGFR2 C382R FGFR2 N549D | Erdafitinib | intrahepatic cholangiocarcinoma | predicted - resistant | detail... |
FGFR2 C382R FGFR2 N549D | Futibatinib | intrahepatic cholangiocarcinoma | conflicting | detail... |
FGFR2 C383R FGFR2 N550D | Lirafugratinib | intrahepatic cholangiocarcinoma | sensitive | detail... |
FGFR2 Y375C | Futibatinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 C382R | Futibatinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
BRAF F595L | Cetuximab + Trametinib | intrahepatic cholangiocarcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02428855 | Phase II | Dasatinib | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | Completed | USA | 0 |
NCT02632305 | Phase II | Cisplatin + Gemcitabine + Nab-paclitaxel | A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC) | Active, not recruiting | CAN | 0 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT02834780 | Phase I | H3B-6527 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma | Completed | USA | ITA | GBR | FRA | ESP | CAN | BEL | 4 |
NCT03230318 | Phase II | Derazantinib | Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01) | Completed | USA | ITA | IRL | GBR | FRA | ESP | DEU | CHE | CAN | BEL | 1 |
NCT03684811 | Phase Ib/II | Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | Completed | USA | GBR | FRA | ESP | AUS | 1 |
NCT03781934 | Phase Ib/II | MIV-818 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | Active, not recruiting | GBR | ESP | BEL | 1 |
NCT03942328 | Phase II | Atezolizumab + Bevacizumab + PCV13 vaccine PCV13 vaccine | Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer | Recruiting | USA | 0 |
NCT04003636 | Phase III | Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) | Active, not recruiting | USA | TUR | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 8 |
NCT04057365 | Phase II | DKN-01 + Nivolumab | A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | Terminated | USA | 0 |
NCT04093362 | Phase III | Futibatinib Cisplatin + Gemcitabine | Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3) | Terminated | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 8 |
NCT04175912 | Phase II | Carboplatin + MLN4924 + Paclitaxel MLN4924 | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | Active, not recruiting | USA | 0 |
NCT04203160 | Phase Ib/II | Cisplatin + Gemcitabine Cisplatin + CPI-613 + Gemcitabine | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) | Completed | USA | 0 |
NCT04301011 | Phase Ib/II | TBio-6517 Pembrolizumab + TBio-6517 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) | Terminated | USA | CAN | 1 |
NCT04301778 | Phase II | Axatilimab + Durvalumab | Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma | Completed | USA | 0 |
NCT04306367 | Phase II | Olaparib + Pembrolizumab | Study of Pembrolizumab and Olaparib in Bile Duct Cancer | Active, not recruiting | USA | 0 |
NCT04466891 | Phase II | ZW25 | A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01) | Completed | USA | ITA | GBR | FRA | ESP | CAN | 3 |
NCT04704154 | Phase II | Nivolumab + Regorafenib | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Completed | USA | ITA | GBR | FRA | BEL | 3 |
NCT04708067 | Phase I | Bintrafusp alfa | Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma | Active, not recruiting | USA | 0 |
NCT04907851 | Phase II | Denosumab + RXC004 Denosumab + Pembrolizumab + RXC004 | A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86) | Completed | GBR | AUS | 0 |
NCT04941287 | Phase II | Atezolizumab + Varlilumab Atezolizumab + Cobimetinib + Varlilumab | Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of A Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | Active, not recruiting | USA | 0 |
NCT04969887 | Phase II | Ipilimumab + Nivolumab | Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) | Active, not recruiting | NZL | AUS | 0 |
NCT04976634 | Phase II | Belzutifan + Lenvatinib + Pembrolizumab | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | Recruiting | USA | NZL | NLD | ISR | FRA | ESP | BEL | AUS | 2 |
NCT04989218 | Phase Ib/II | Cisplatin + Durvalumab + Gemcitabine + Tremelimumab | Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) (ICC) | Terminated | USA | 0 |
NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN | 5 |
NCT05174650 | Phase II | Atezolizumab + Derazantinib | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | Active, not recruiting | DEU | 0 |
NCT05220722 | Phase Ib/II | Pembrolizumab + SD-101 Ipilimumab + Nivolumab + SD-101 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | Active, not recruiting | USA | 0 |
NCT05221320 | Phase II | Hydroxychloroquine + Ulixertinib | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | Terminated | USA | 0 |
NCT05223816 | Phase II | Nivolumab + VG161 VG161 | An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma | Recruiting | USA | 0 |
NCT05239169 | Phase II | Capecitabine + Durvalumab + Tremelimumab Durvalumab + Tremelimumab | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | Active, not recruiting | DEU | 0 |
NCT05286814 | Phase II | Fluorouracil + Leucovorin + NHS-IL12 + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + NHS-IL12 | M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma | Recruiting | USA | 0 |
NCT05325866 | Phase I | Bemarituzumab | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) | Recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
NCT05506943 | Phase II | Paclitaxel CTX-009 + Paclitaxel | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers | Active, not recruiting | USA | 0 |
NCT05512377 | Phase II | BI 907828 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CHE | BEL | AUS | 5 |
NCT05514912 | Phase II | Cisplatin + Gemcitabine + Nab-paclitaxel Cisplatin + Gemcitabine + Infigratinib + Nab-paclitaxel | Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial | Withdrawn | 0 | |
NCT05564403 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | Recruiting | USA | 0 |
NCT05565794 | Phase II | Pemigatinib | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | Recruiting | DEU | 0 |
NCT05627063 | Phase I | ABSK121 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05655949 | Phase II | Cisplatin + Durvalumab + Gemcitabine + Yttrium-90 microsphere therapy | Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio | Recruiting | USA | 0 |
NCT05967182 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | Recruiting | USA | 0 |
NCT06017297 | Phase II | Cisplatin + Durvalumab + Gemcitabine + Tremelimumab | Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma (ESR-22-21719) | Withdrawn | 0 | |
NCT06050252 | Phase II | Cisplatin + Durvalumab + Gemcitabine | Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery | Recruiting | USA | 0 |
NCT06058663 | Phase I | Durvalumab + Tremelimumab | Radioembolization With Tremelimumab and Durvalumab for Locally Advanced, Unresectable Intrahepatic Cholangiocarcinoma | Recruiting | USA | 0 |
NCT06160752 | Phase I | TYRA-200 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201) | Recruiting | USA | 0 |
NCT06282575 | Phase III | Cisplatin + Durvalumab + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Durvalumab + Gemcitabine + ZW25 Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab + ZW25 Cisplatin + Gemcitabine + ZW25 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Recruiting | USA | SWE | ROU | ITA | ISR | FRA | FIN | ESP | CAN | ARG | 8 |
NCT06360354 | Phase I | AMG193 + Cisplatin + Gemcitabine + Pembrolizumab AMG193 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin AMG193 + Gemcitabine + Nab-paclitaxel | A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion | Recruiting | USA | NLD | ITA | GRC | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 2 |
NCT06375915 | Phase II | Cisplatin + Durvalumab + Gemcitabine | Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy (PM-CARE) | Recruiting | ITA | 0 |
NCT06529718 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Ivonescimab | Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients (SEVILLA) | Not yet recruiting | GBR | FRA | BEL | 0 |
NCT06546969 | Phase I | Cisplatin + Durvalumab + Gemcitabine | Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer | Recruiting | USA | 0 |
NCT06569225 | Phase II | AZD2936 + Cisplatin + Gemcitabine + Nab-paclitaxel | Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA (NEOLANGIO) | Not yet recruiting | CAN | 0 |